Green Light For Chemokine Receptors

April 09, 1997

Potent inhibition of HIV-1 entry into macrophages has been demonstrated for the first time. A Glaxo Wellcome collaborative study showed that a chemically modified chemokine, AOP-RANTES, inhibited HIV-1 entry not only into lymphocytes but also into macrophages. This inhibition was achieved at the nanomolar level.

"We are excited by these results, which encourage us to believe that chemokine receptors are going to be suitable targets for drug discovery", said Dr Amanda Proudfoot, a research scientist at Glaxo Wellcome's Geneva Biomedical Research Institute. "There is still a long way to go and questions remain about the eventual clinical utility of chemokine receptor antagonists - but these results are very promising."

This research is the latest stage in the process of validating chemokine receptors as drug targets and further research is underway to explore their potential in the treatment of HIV/AIDS and asthma. Glaxo Wellcome has already set up a screening programme to hunt for small molecule antagonists of the chemokine receptor CCR5.

Chemokines, or chemoattractant cytokines, are a large family of small proteins that regulate the movement of white blood cells. They exert their effects by binding to specific receptors. Researchers believe that chemokine receptor antagonists hold considerable potential for the treatment of diseases such as asthma, arthritis and HIV/AIDS.

Chemokines in asthma

Certain chemokines, including one called RANTES, are potent activators and promote migration of T cells, eosinophils, and monocytes - cells that play an important role in inflammation. In particular, eosinophils are thought to contribute to tissue damage in the airways of patients with asthma.

Recent research from Glaxo Wellcome has shown that a modified form of RANTES, Met-RANTES, can effectively block this activity. The researchers hope that a drug with similar properties will eventually lead to a new class of anti-inflammatory drugs especially useful for patients whose asthma is not well controlled by current therapies.

Chemokines in HIV/AIDS

Two chemokine receptors, CCR5 and CXCR4, have been found to act as co-receptors essential for HIV infection. The CD4 receptor plus one of these chemokine receptors is required for HIV entry into host cells. HIV uses the CCR5 receptor to gain entry into macrophages and lymphocytes during initial infection and the asymptomatic phase of disease. Later on, because HIV mutates rapidly, viruses able to infect T cells using the CXCR4 receptor become more prominent. Symptoms appear after this later form of HIV predominates.

Significant progress has been made towards validating CCR5 as a drug target. Three chemokines, RANTES, MIP-1a and MIP-1b, interact with the CCR5 receptor and have been shown to inhibit the entry of HIV into lymphocytes. A recent Glaxo Wellcome collaborative study with the Chester Beatty Institute in London published in Science (Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist, Science, 11 April 1997, 276: 276-279 shows that in contrast to the naturally occurring chemokine, a chemically modified version of RANTES, AOP-RANTES made by Dr Robin Offord of the University of Geneva, is significantly more potent, and in addition is also able to block HIV entry into macrophages.

As Dr Proudfoot explained, "HIV resides in certain tissues, in cells such as macrophages, during the early phase of disease, when blood levels of virus are still undetectable. Our findings suggest a treatment approach that could be used before AIDS symptoms appear to stop HIV from spreading to cells in the tissues."

AOP-RANTES blocks HIV entry by fully occupying all CCR5 receptors on the macrophage surface. Scientists hope that by attacking HIV early on, they can delay or stop progression to disease. All existing HIV/AIDS treatments attack viral enzymes; chemokine receptor antagonists would offer a completely new approach - targeting host cells to prevent HIV entry. Dr Tim Wells, the Glaxo Wellcome chemokine project leader in Geneva, said "We believe that our findings suggest an alternative treatment approach that could be used alongside current therapies and have set up a screening programme to look for candidate molecules."

Chemokine receptor antagonists as medicines

There is undoubtedly great interest in chemokine receptor antagonists as potential medicines. CCR5 and CXCR4 are 7 transmembrane, G protein linked receptors, a type of receptor well known to pharmaceutical companies like Glaxo Wellcome, many of whose existing drugs also block 7 transmembrane receptors.

However, chemokines are vitally important immune system components and interfering with their normal function could have side effects. Data are already available that suggest that blocking CCR5 may not lead to serious side effects; people with mutations in the CCR5 receptor do not have any obvious health problems. Further, the mutations in the CCR5 receptor appear to confer some resistance to HIV infection. There are several cases of people with mutant CCR5 receptors who have repeatedly had high risk contact with HIV infected patients, but have themselves remained HIV negative.

For further information contact:


Philip Connolly, Group Public Affairs, Glaxo Wellcome plc: Tel: +44 181 966 8185, Fax: +44 181 966 8827


Dr Amanda Proudfoot, Glaxo Wellcome Research & Development S.A., Geneva Biomedical Research Institute: Tel +41 22 706 9800


Emma Weitkamp, Hayhurst Conington Cripps Ltd: Tel: + 44 1483 414182, Fax: +44 1483 414157


GlaxoSmithKline US

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.